Finally, the ongoing exploration of combination therapies, such as BRAF/MEK inhibitors paired with novel immune modulators or metabolic reprogramming agents, is crucial for determining their efficacy and safety in patients with BRAF-mutant melanoma. The gene discussed is MAP2K7; the disease is melanoma.